Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

harryvanluik Mar. 19 at 4:39 PM

$EDIT Market Beat issued an interesting report. I quote: "Several brokerages have commented on EDIT. Robert W. Baird set a $6.00 target price on Editas Medicine in a report on Monday, March 9th. JonesTrading raised Editas Medicine from a "hold" rating to a "buy" rating and set a $8.00 target price for the company in a research note on Tuesday, March 10th. TD Cowen reiterated a "buy" rating on shares of Editas Medicine in a report on Monday, March 9th. Weiss Ratings reissued a "sell (e+)" rating on shares of Editas Medicine in a research note on Wednesday, January 21st. Finally, Chardan Capital restated a "buy" rating and set a $3.50 price target on shares of Editas Medicine in a report on Monday, March 9th."

0 · Reply

Whoami1989 Mar. 18 at 1:52 PM

$EDIT erection dysfunctional dick

1 · Reply

DoctrBenway Mar. 17 at 7:36 PM

$EDIT $IOVA I'm thinking shorting must be genetic. How else do you explain all the facial abnormalities?

0 · Reply

0x126 Mar. 16 at 2:22 PM

$EDIT go to 4 already ffs The jump to 7 and let's wait for trial announcement mid of year.

0 · Reply

burbs88 Mar. 16 at 1:59 PM

$EDIT No position. Peculiar month here. Not a huge fan of the company but you have to consider the possibility of a buyout with it trading so cheap.

2 · Reply

Whoami1989 Mar. 13 at 4:39 PM

$EDIT Dear pumpers - stop pumping your shit out of yiur rear end

0 · Reply

Erminiottone Mar. 12 at 7:17 PM

$EDIT chino Feng Zhang fucked you al hahhahahah

0 · Reply

Erminiottone Mar. 12 at 7:12 PM

$EDIT going to penny !

0 · Reply

Taurusthebullman Mar. 11 at 6:03 PM

$EDIT I read that they're doing their fireside presentation tomorrow morning at 8:00 a.m. at the Barclays conference.. fingers crossed for that

0 · Reply

Robert_Dempster Mar. 11 at 2:37 PM

$EDIT so undervalued its time to shine were moving up 📈🐂

0 · Reply

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 9, 2026, 7:00 AM EDT - 12 days ago

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Feb 23, 2026, 9:00 AM EST - 26 days ago

Editas Medicine to Participate in Upcoming Investor Conferences

Jan 19, 2026, 2:20 AM EST - 2 months ago

Genflow Biosciences PLC Announces Directorate Change

Nov 10, 2025, 7:00 AM EST - 4 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 4 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 14, 2025, 6:18 PM EDT - 5 months ago

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 5 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 7 months ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 10 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 10 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 11 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 11 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 11 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 11 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 11 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 1 year ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 1 year ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

harryvanluik Mar. 19 at 4:39 PM

0 · Reply

Whoami1989 Mar. 18 at 1:52 PM

$EDIT erection dysfunctional dick

1 · Reply

DoctrBenway Mar. 17 at 7:36 PM

$EDIT $IOVA I'm thinking shorting must be genetic. How else do you explain all the facial abnormalities?

0 · Reply

0x126 Mar. 16 at 2:22 PM

$EDIT go to 4 already ffs The jump to 7 and let's wait for trial announcement mid of year.

0 · Reply

burbs88 Mar. 16 at 1:59 PM

$EDIT No position. Peculiar month here. Not a huge fan of the company but you have to consider the possibility of a buyout with it trading so cheap.

2 · Reply

Whoami1989 Mar. 13 at 4:39 PM

$EDIT Dear pumpers - stop pumping your shit out of yiur rear end

0 · Reply

Erminiottone Mar. 12 at 7:17 PM

$EDIT chino Feng Zhang fucked you al hahhahahah

0 · Reply

Erminiottone Mar. 12 at 7:12 PM

$EDIT going to penny !

0 · Reply

Taurusthebullman Mar. 11 at 6:03 PM

$EDIT I read that they're doing their fireside presentation tomorrow morning at 8:00 a.m. at the Barclays conference.. fingers crossed for that

0 · Reply

Robert_Dempster Mar. 11 at 2:37 PM

$EDIT so undervalued its time to shine were moving up 📈🐂

0 · Reply

SmartMoneyTradez Mar. 11 at 2:24 PM

$EDIT all out

0 · Reply

harryvanluik Mar. 11 at 1:23 PM

$EDIT All ready for another huge move upwards?

0 · Reply

StockJelli Mar. 10 at 9:43 PM

Hope everyone came out with profits today. Here are the momentum stocks in the after hours. $PLYX $MGNX $UAMY $NIO $EDIT

0 · Reply

Realy Mar. 10 at 8:34 PM

$EDIT $4’ish, the bet I am on the biggest stretch of this pop- any insights? ☕️

0 · Reply

Whoami1989 Mar. 10 at 7:30 PM

$EDIT once again, day traders are dumb as fuck

1 · Reply

ZacksResearch Mar. 10 at 3:56 PM

$EDIT surges 16% on impressive Q4 results! Despite a 19% drop in collaboration and other R&D revenues YoY, Editas Medicine beat the Zacks Consensus Estimate significantly, thanks to lower operating expenses. The stock's rally is driven by strong cost management. See why investors are optimistic about Editas 👉 https://www.zacks.com/stock/news/2881685/edit-stock-up-on-narrower-than-expected-q4-loss-revenues-rise-yy?cid=sm-stocktwits-2-2881685-body-36806&ADID=SYND_STOCKTWITS_TWEET_2_2881685_BODY_36806

0 · Reply

ChaseDuni Mar. 10 at 3:08 PM

$EDIT exactly what I needed

0 · Reply

ZacksResearch Mar. 10 at 2:56 PM

$EDIT just popped 16% — is momentum finally building? The company reported a narrower-than-expected Q4 loss and beat revenue estimates, while pushing its EDIT-401 gene-editing candidate closer to its first human study expected in 2026. Is this the catalyst biotech bulls have been waiting for? Full breakdown here 👉 https://www.zacks.com/stock/news/2881685/edit-stock-up-on-narrower-than-expected-q4-loss-revenues-rise-yy?cid=sm-stocktwits-2-2881685-teaser-36783&ADID=SYND_STOCKTWITS_TWEET_2_2881685_TEASER_36783

0 · Reply

SmartMoneyTradez Mar. 10 at 2:51 PM

$EDIT Multi day runner. Told ya this will keep going. Looking for profits 50%-300%+. Everything to the moon🚀 I Post quality over quantity ✅You are destined to be RICH💰✅, 🚫 NO guessing /gambling. If you missed this one, be sure to turn on notifications for the next one 🚨 $XTKG $ARTW $TOPS $KIDZ

0 · Reply

alexx013 Mar. 10 at 2:50 PM

$EDIT

0 · Reply

StockBraker Mar. 10 at 2:40 PM

$EDIT Today's PTs issued.

1 · Reply

1GreenDay99RedDays Mar. 10 at 2:39 PM

$EDIT and it’s still wildly undervalued

0 · Reply

Market Cap	229.02M
Revenue (ttm)	40.52M
Net Income (ttm)	-160.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-395.01%
Debt to Equity Ratio	0.00

Volume	1,780,200
Avg Vol	1,770,416
Day's Range	N/A - N/A
Shares Out	97.87M
Stochastic %K	18%
Beta	2.16
Analysts	Sell
Price Target	$5.19